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DOI:10.1097/HJH.0b013e32834fa8b0Stiffness of elastic arteries like the aorta predicts
cardiovascular risk. By directly reflecting arterial stiffness,
having the best predictive value for cardiovascular outcome
and the ease of its measurement, carotid-femoral pulse
wave velocity is now considered the gold standard for
arterial stiffness assessment in daily practice. Many
different measurement procedures have been proposed.
Therefore, standardization of its measurement is urgently
needed, particularly regarding the distance measurement.
This consensus document advises on the measurement
procedures in general and provides arguments for the use
of 80% of the direct carotid-femoral distance as the most
accurate distance estimate. It also advises the use of
10m/s as new cut-off value for carotid-femoral pulse
wave velocity.
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M
any studies have shown that the stiffness of elastic
arteries like the aorta independently predicts
cardiovascular risk [1–3]. The predictive value
of aortic stiffness, measured as carotid-femoral pulse wave
velocity (PWV), was largely superior in the Framingham
Heart Study to brachial artery stiffness (carotid-radial PWV),
augmentation index, central pulse pressure and pulse
pressure amplification [4]. The same holds in patients with
end-stage renal disease, with carotid-femoral PWV (cfPWV)
also superior to brachial artery and femorotibial stiffness [5].
By directly reflecting arterial stiffness, having the best
predictive value for cardiovascular events and the ease of
its measurement, cfPWV is now considered the gold stand-
ard for arterial stiffness assessment [1]. The 2007 European
Society of Hypertension–European Society of Cardiology
(ESH–ESC) Guidelines for the Management of Hyper-
tension consider a high cfPWV as target organ damage [6].
Carotid-femoral PWV is calculated by dividing traveled
distance by transit time (PWV¼distance/time). The large
majority of devices quite accurately measure transit time asCopyright © Lippincott Williams & Wilkins. Unauth
Journal of Hypertensionthe time delay between the arrival of the pulse wave at the
common carotid artery and the common femoral artery.
This measurement can be done directly on the same pulse
wave, or indirectly by subtracting the time delay between
the Rtop of the electrocardiogram to the common carotid
artery from the time delay between the Rtop of the electro-
cardiogram to the common femoral artery. The traveled
distance should also be measured accurately since small
differences may influence the absolute value of PWV [1,7].
However, there is no consensus on how this distance is
ideally measured and many different distances have been
proposed (Table 1). A standardization of the measurement
technique is requested since each distance definition results
in a different PWV value [8,9] increasing confusion among
users. Whereas the cut-off value of 12m/s in the European
guidelines [6] only applies to the full (100%) direct carotid-
femoral (common carotid artery–common femoral artery)
distance, the recently published reference values are
based on 80% of the common carotid artery—commonorized reproduction of this article is prohibited.
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TABLE 1. Comparison of MRI measured traveled distance (reference distance) and estimated distance (from [11])
Reference distance mean (SD) Tape measure distance mean (SD)
Tape measure – reference
distance mean (SD)
(AA FA) (AACA) (CA FA) (CA SN) 48.3 (4.1) 2.4 (3.8)
50.7 (4.2) (CA-FA) - (CA-SSN) 53.0 (4.1) 2.3 (3.8)
(SN FA) (CA SN) 35.9 (4.3) 14.8 (3.9)
(SSN FA) (CA SSN) 45.5 (4.5) 5.1 (3.5)
(SSNUMB) þ (UMB FA) 57.7 (4.5) 7.2 (4.0)
(CA FA) 63.6 (4.4) 13.0 (4.2)
[(SSNUMB)þ (UMB FA)] (CA SN) 42.3 (4.7) 8.2 (4.1)
[(SSNUMB)þ (UMB FA)] (CA SSN) 47.0 (4.7) 3.5 (4.1)
(CA FA)0.8 50.9 (3.5) 0.3 (3.8)
Body height/4þC (7.28) 50.2 (2.3) 0.5 (3.9)
Body height0.29 49.8 (2.6) 0.9 (4.0)y
AA, ascending aorta; CA, common carotid artery; FA, common femoral artery; SN, sternal notch; SSN, suprasternal notch; UMB, umbilicus. Data from [11]. Reference distance, the real
traveled aortic path length determined by MRI; tape measure distance, body surface distance obtained by tape measure.
P<0.001.
yP<0.05.
Van Bortel et al.femoral artery distance [7]. In addition, although conversion
formulas have been proposed to calculate subtracted
distance (suprasternal notch to common femoral artery
minus suprasternal notch to common carotid artery) from
direct distance and vice versa [10], these formulas are
approximations and introduce additional error.
Recently different proposed distances have been
compared with the real traveled distance measured by mag-
netic resonance imaging (MRI). From the MRI images a
centerline was constructed in the lumen of the arteries.
Following these arterial centerlines, the real traveled
distance was defined as the ascending aorta (from aortic
valve) to right common femoral artery distance minus
ascending aorta to right common carotid artery distance
[11]. This study showed that the direct carotid-femoral dis-
tance largely overestimates the real traveled distance by
25.4%, whereas the subtracted distances using the
distances to common femoral artery and common carotid
artery from suprasternal and sternal notch substantially
underestimate the real traveled distance by 10.3 and
29.2%, respectively. Of all currently used distances the
80% of the direct carotid-femoral distance (common carotid
artery common femoral artery 0.8) appeared the most
accurate, only slightly overestimating the real traveled
distance by 0.4%. Two other estimates performing relatively
well were both based on body height (body height/4þ 7.28
proposed by Weber et al. [12] and body height 0.29
proposed by Filipovsky et al. [13]) underestimating the
traveled distance by 1.0 and 1.8%, respectively. The model
obtained from a multiple linear regression analysis
(r2¼ 0.64) was: real traveled distance¼ (0.286 common
carotid artery common femoral artery)þ (0.101 age)þ
(0.159weight)þ 16.165, with common carotid artery
common femoral artery in cm, age in years andweight in kg.
This best fit formula appears too complicated to be
applied in daily practice, unless built in a dedicated device.
The same study also confirmed the data by Sugawara
et al. [14], showing a distance which increases with age.
In the population studied by Huybrechts et al. [11],
the variation in distance between the (common carotid
artery common femoral artery 0.8) tape measure dis-
tance and the MRI measured real traveled distance was
largely explained by increasing age (30%) and to a muchCopyright © Lippincott Williams & Wilkins. Unaut
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it was tested in the same population whether a simple and
for daily practice acceptable modification of the (common
carotid artery common femoral artery 0.8) distance
taking into account age would be more accurate. The tested
formula adjusts the (common carotid artery common
femoral artery 0.8) distance for age by adding 1mm/year
for an age above 50 and subtracting 1mm/year for an
age below 50, respectively (Table 2). Although on the
population level (Table 2a) this age-adjusted formula
performed better; this was not the case on an individual
level in the age group between 50 and 76 years (Table 2b),
which may be considered the more relevant group for
targeting. More data in the very elderly may be needed.
Thus, at this stage, we advise to use the simple unadjusted
(common carotid artery common femoral artery 0.8)
distance as standard distance for daily practice, for three
main reasons: the age adjustment did not perform better in
theolder agegroup; the adjusted formula is less easy touse in
daily practice; and as in the study by Sugawara et al. [14] the
age-dependent elongationof the aortic path length is limited.
This consensus panel is aware that the so-called ‘real’
traveled distance of cfPWV is not a simple unidirectional
path length since at the time the pulse wave travels up the
brachiocephalic and carotid artery, it also travels down the
aortic arch. MRI measurements as outlined above are valid
only after the assumption that these velocities are the same
in both directions, and this may not be the case. In animals
PWV in the carotid artery may be higher by 2–3m/s than in
the aortic arch [15]. Rough calculations from studies show-
ing both common carotid stiffness and cfPWV suggest that
the difference in PWV between common carotid artery
and aortic arch/descending aorta may be smaller in
humans [16] and is probably affecting cfPWV less than
3%. The present data also are based on measurements at
the right common carotid artery and common femoral
artery. It is not excluded that this may be slightly different
for measurements at the left side.
The current cut-off value, proposed in the 2007 ESH–
ESC Guidelines for the Management of Hypertension [6], is
12m/s, above which there is an increased risk for cardio-
vascular events. This value was selected because it corre-
sponded to a rough estimate of high cardiovascular riskhorized reproduction of this article is prohibited.
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TABLE 2. Error of distance estimation (CA FA)0.8 and the age-adjusted variant [(CA FA)0.8þ (0.1 (age-50)] compared to MRI
measured reference distance
(a) Mean difference from reference distance
Age <50 (N¼52) Age >50 (N¼46) Total (N¼98)
Reference distance (Lref) (cm) 49.0 (3.2) 52.5 (4.4) 50.7 (4.2)
(CA FA)0.8 Lref (cm) 2.05 (3.3) 1.75 (3.4) 0.27 (3.8)
(CA FA)0.8) þ 0.1 (age 50)  Lref (cm) 0.44 (3.3) 0.40 (3.2) 0.05 (3.2)
Lref ¼ reference distance ¼ MRI measured real traveled distance (AA FA) (AACA);
AA, ascending aorta; CA, common carotid artery; FA, common femoral artery; P<0.05 vs. reference distance
(b) Cumulative percentage of measurements differing less than 2, 5, 10 and 15% from the reference distance
Age <50 (N¼52) Age >50 (N¼46) Total (N¼98)
In % T TC T TC T TC
<2% difference with the reference distance 32.7 50.0 80.4 69.6 55.1 59.2
<5% difference with the reference distance 46.2 69.2 93.5 82.6 68.4 75.5
<10% difference with the reference distance 78.8 96.2 95.7 95.7 86.7 95.9
<15% difference with the reference distance 98.1 100.0 100.0 97.8 99.0 99.0
Reference distance¼MRI measured real traveled distance (AA FA) (AACA); T¼ (CA FA)0.8; TC¼ [(CA FA) 0.8)þ (0.1 x(age50)].
AA, ascending aorta; CA, common carotid artery; FA, common femoral artery.
Measurement of aortic stiffness using carotid-femoral PWVfrom longitudinal data available at that time in different
populations of hypertensive patients [17,18], older adults
[19] and in the general population [20]. Since that time,
many other studies provided either longitudinal [2,4,21] or
cross-sectional [7] data supporting this cut-off value.
This cut-off value of 12m/s was based on the 100%
direct common carotid artery common femoral artery
distance measurement. Adapted to the new standard dis-
tance (common carotid artery common femoral artery
0.8), it would become 9.6m/s. We propose 10m/s as new
standard cut-off value for cfPWV, because this is an easy
figure to use in daily practice. In addition, and more
important, this value is at the upper part of the second
quartile in the Framingham Heart Study and represents in
this general population with a mean age of 63 years about
4% risk for a first major cardiovascular event within the next
8 years [4]. One should be aware of the limitations of the use
of a fixed cut-off value. The 2007 guidelines mention that
‘although the relationship between aortic stiffness and
events is continuous, the threshold has been suggested
as a conservative estimate of significant alterations of aortic
function in middle-aged hypertensive patients’. It, there-
fore, is not obvious that a fixed age and BP-independent
cut-off value is the best risk predictor in different popu-
lations [7]. This should be further investigated.
Finally, one should keep in mind that as for BP measure-
ment, standardization of patient conditions and repeated
measurements is of utmost importance [1,22,23]. We
advise to perform at least two measurements. If these
differ by more than 0.5m/s, a third measurement should
be performed. The PWV value should be the median of
those measurements. The median value has the advantage
over the mean value that the operator does not have to
calculate and that the influence of outliers is reduced or
ruled out. In addition, it is also very important to take
the tape measure distance in a straight line. If this is not
possible as in severe obesity, an infantometer used upside-
down can provide a more reliable distance measurement.
These other recommendations on user procedures are
summarized below.Copyright © Lippincott Williams & Wilkins. Unauth
Journal of HypertensionOther recommendations on user procedures (adapted
from [1,22,23]):or(1)izedMeasurements should be performed in a quiet
room with stable room temperature.(2) Perform measurements in supine position after at
least 10min of rest.(3) Measurements should preferentially be done at
the right common carotid and common femoral
arteries.(4) Because of diurnal variations repeated measure-
ments should be done at the same time of the day.(5) No meal, caffeine or smoking is allowed within 3 h
before measurement.(6) Speaking and sleeping are not allowed during
measurements.(7) Data should be mean of registrations during at least
one respiratory cycle (about 5–6 s).(8) Be aware of possible white coat effects.
(9) Measure distance in a straight line. If not possible
with a tape measure, the upside-down use of
an infantometer may be helpful.(10) Take mean of at least two measurements; if
difference between the two measurements is
more than 0.5m/s, perform a third measurement
and take the median value.(11) Situations in which measurement of cfPWV should
not be performed: arrhythmia, unstable clinical
situation, high-grade stenosis of carotid artery,
carotid sinus syndrome.In conclusion, this expert consensus document advises
to standardize patient conditions and user procedures
for the measurement of aortic stiffness using cfPWV (see
Box 1). It advises to use 80% of the direct carotid-femoral
(common carotid artery common femoral artery 0.8)
tape measure distance as new standard for daily practice,
because this appears to be the most accurate body surface
distance estimate, is easy to use, and is less influenced by
large bellies and large breasts. In addition, it allows the use reproduction of this article is prohibited.
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Box 1 Recommendations for the measurement of carotid-femoral pulse
wave velocity in daily practice
 Use a dedicated and validated device to measure pulse wave travel time (t)
between common carotid and common femoral arteries
 Measure direct straight distance between the two measurement sites with
tape measure and use 80% of this distance as pulse wave traveled distance
(d)
 Calculate PWV by the formula PWV¼d/t (expressed as m/s)
 Use 10m/s as standard cut-off value for carotid-femoral PWV in the
prediction of cardiovascular events
 Take into account the other recommendations on user procedures
Van Bortel et al.of the previously published normal and reference values
directly without conversion [7]. Finally, this document also
advises to adapt the cut-off value for cfPWV to 10m/s.
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